In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme
Study context
- Population
- Virtual patients with established atherosclerotic cardiovascular disease (ASCVD) (prior myocardial infarction (MI), ischemic stroke or symptomatic peripheral arterial disease (PAD)) and fasting LDL-C ≥ 70 mg/dL despite stable lipid-lowering therapy
- Planned comparison
- Inclisiran vs placebo, ezetimibe or evolocumab
- Primary endpoint
- Co-primary: time to first 3P-MACE (CV death, nonfatal MI or nonfatal ischemic stroke (IS)) and time to CV death
- Follow-up
- 5 years
Methodological detailsdesign paper, multi-arm, idealized crossover design, knowledge-based mechanistic model of ASCVD
- Design paper
- Multi-arm
- Idealized crossover design
- Knowledge-based mechanistic model of ASCVD
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
In-silico trial emulation to predict the cardiovascular protection of new lipid-lowering drugs: an illustration through the design of the SIRIUS programme. Eur J Prev Cardiol. Published 5 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →